论文部分内容阅读
目的:评估获得性免疫缺陷综合征(AIDS)患者抗病毒治疗后并发严重不良反应,更换洛匹那韦/利托那韦片(LPV/r)的疗效。方法:回顾性分析8例AIDS患者接受三联抗病毒治疗后并发严重不良反应,人类免疫缺陷病毒(HIV)RNA已降至<40拷贝/m L,更换LPV/r单药维持治疗后监测患者症状和体征,CD4~+T淋巴细胞以及HIV RNA。结果:8例患者换方案后随访2~4年,不良反应症状好转,HIV RNA均良好控制,CD4~+T淋巴细胞均稳定上升。结论:AIDS患者接受三联抗病毒治疗HIV载量降至检测下限后给予LPV/r单药维持治疗,抗病毒效果良好,而且因核苷类抗反转录酶药物引起的严重不良反应也明显好转。
OBJECTIVE: To assess the efficacy of replacement of lopinavir / ritonavir (LPV / r) in patients with Acquired Immune Deficiency Syndrome (AIDS) after severe antiviral therapy with serious adverse reactions. Methods: Eight patients with AIDS were retrospectively analyzed for serious adverse reactions after receiving triple anti-virus therapy. The RNA of HIV was reduced to <40 copies / mL. Patients were monitored after LPV / r monotherapy And signs, CD4 ~ + T lymphocytes and HIV RNA. Results: Eight patients were followed up for 2 to 4 years after treatment. The symptoms of adverse reactions improved. HIV RNA was well controlled and CD4 ~ + T lymphocytes stably increased. CONCLUSIONS: HIV patients receiving triple triple antiviral therapy have been treated with LPV / r single-agent maintenance therapy after their HIV load has fallen to the lower limit of detection. The antiviral effect is good, and the serious side effects caused by nucleoside anti-retroviral drugs are also significantly improved .